Back HCV Treatment

EASL 2017: AbbVie Combination Cures Most People with Genotype 3 Hepatitis C

AbbVie's pangenotypic direct-acting antiviral combination of 2 drugs cured 95% of people with early-stage genotype 3 hepatitis C virus (HCV) infection, the hardest genotype to treat, according to results of the ENDURANCE-3 trial presented at the EASL International Liver Congress this week in Amsterdam.

alt

Read more: